Early Initiation of PCSK9 Inhibitor Therapy versus Placebo in Patients with Acute Coronary Syndrome: A Systematic Review and Meta-Analysis

Link to article at PubMed

Am J Cardiol. 2023 Oct 22:S0002-9149(23)01196-7. doi: 10.1016/j.amjcard.2023.10.043. Online ahead of print.


In patients with stable atherosclerotic cardiovascular disease, PCSK9 inhibitors (PCSK9i) have shown a 50-60% reduction in LDL-C from baseline, added to high-intensity statin therapy. However, less is known about the impact of PCSK9i in the setting of an acute coronary syndrome (ACS). Therefore, we performed a systematic review and meta-analysis comparing PCSK9i with placebo in the setting of ACS, added to guideline directed high-intensity or maximally tolerated statin therapy. We included randomized controlled trials (RCTs) with initiation of PCSK9i or placebo within 1 week of presentation or percutaneous coronary intervention for ACS. PubMed, EMBASE, and Cochrane Central were searched. This study followed Cochrane and PRISMA recommendations. Six RCTs were included, totalizing 996 patients of whom 503 (50.5%) received PCSK9i. Mean follow-up ranged from 4 to 52 weeks. LDL-C (MD -44 mg/dL; CI -54.3 to -33.8; p<0.001) and Lp(a) levels (MD -24.0 nmol/L; CI -43.0 to -4.9; p=0.01) were significantly lower at follow-up with PCSK9i. Similarly, total cholesterol (MD -49.2 mg/dL; CI -59 to -39.3), triglycerides (MD -19 mg/dL; CI -29.9 to -8.2) and Apo B (MD -33.3 mg/dL; CI -44.4 to -22.1) were significantly reduced with PCSK9i. In conclusion, in patients with ACS, early initiation of PCSK9i, added to statin, significantly reduces LDL-C and Lp(a) as compared with placebo. Whether the differences in these atherogenic lipoproteins translate into a reduction in clinical endpoints is yet to be determined.

PMID:37875235 | DOI:10.1016/j.amjcard.2023.10.043

Leave a Reply

Your email address will not be published. Required fields are marked *